Intermediate monocytes correlate with CXCR3+ Th17 cells but not with bone characteristics in untreated early rheumatoid arthritis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
10
2020
accepted:
14
03
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is associated with development of generalized osteoporosis. Bone-degrading osteoclasts are derived from circulating precursor cells of monocytic lineage, and the intermediate monocyte population is important as osteoclast precursors in inflammatory conditions. T cells of various subsets are critical in the pathogenesis of both RA and associated osteoporosis, but so far, no studies have examined associations between circulating intermediate monocytes, T cell subsets and bone characteristics in patients with RA. The aim of this study was to investigate the frequency of intermediate monocytes in patients with untreated early rheumatoid arthritis (ueRA) compared to healthy controls (HC), and to explore the correlation between intermediate monocytes and a comprehensive panel of T helper cell subsets, bone density and bone microarchitecture in ueRA patients. 78 patients with ueRA fulfilling the ACR/EULAR 2010 criteria were included and compared to 29 age- and sex-matched HC. Peripheral blood samples were obtained before start of treatment and proportions of monocyte subsets and CD4+ helper and regulatory T cell subsets were analyzed by flow cytometry. Bone densitometry was performed on 46 of the ueRA patients at inclusion using DXA and HR-pQCT. Flow cytometric analyses showed that the majority of ueRA patients had frequencies of intermediate monocytes comparable to HC. The intermediate monocyte population correlated positively with CXCR3+ Th17 cells in ueRA patients but not in HC. However, neither the proportions of intermediate monocytes nor CXCR3+ Th17 cells were associated with bone density or bone microarchitecture measurements. Our findings suggest that in early RA, the intermediate monocytes do not correlate with bone characteristics, despite positive correlation with circulating CXCR3+ Th17 cells. Future longitudinal studies in patients with longer disease duration are required to fully explore the potential of intermediate monocytes to drive bone loss in RA.
Sections du résumé
BACKGROUND
Rheumatoid arthritis (RA) is associated with development of generalized osteoporosis. Bone-degrading osteoclasts are derived from circulating precursor cells of monocytic lineage, and the intermediate monocyte population is important as osteoclast precursors in inflammatory conditions. T cells of various subsets are critical in the pathogenesis of both RA and associated osteoporosis, but so far, no studies have examined associations between circulating intermediate monocytes, T cell subsets and bone characteristics in patients with RA. The aim of this study was to investigate the frequency of intermediate monocytes in patients with untreated early rheumatoid arthritis (ueRA) compared to healthy controls (HC), and to explore the correlation between intermediate monocytes and a comprehensive panel of T helper cell subsets, bone density and bone microarchitecture in ueRA patients.
METHODS
78 patients with ueRA fulfilling the ACR/EULAR 2010 criteria were included and compared to 29 age- and sex-matched HC. Peripheral blood samples were obtained before start of treatment and proportions of monocyte subsets and CD4+ helper and regulatory T cell subsets were analyzed by flow cytometry. Bone densitometry was performed on 46 of the ueRA patients at inclusion using DXA and HR-pQCT.
RESULTS
Flow cytometric analyses showed that the majority of ueRA patients had frequencies of intermediate monocytes comparable to HC. The intermediate monocyte population correlated positively with CXCR3+ Th17 cells in ueRA patients but not in HC. However, neither the proportions of intermediate monocytes nor CXCR3+ Th17 cells were associated with bone density or bone microarchitecture measurements.
CONCLUSIONS
Our findings suggest that in early RA, the intermediate monocytes do not correlate with bone characteristics, despite positive correlation with circulating CXCR3+ Th17 cells. Future longitudinal studies in patients with longer disease duration are required to fully explore the potential of intermediate monocytes to drive bone loss in RA.
Identifiants
pubmed: 33770137
doi: 10.1371/journal.pone.0249205
pii: PONE-D-20-32146
pmc: PMC7996983
doi:
Substances chimiques
Receptors, CXCR3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249205Déclaration de conflit d'intérêts
Mattias Lorentzon has received lecture fees from Amgen, Gedeon Richter, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. None of the other authors have any conflict of interests related to this manuscript.
Références
Nat Rev Rheumatol. 2016 Aug;12(8):472-85
pubmed: 27383913
Scand J Rheumatol. 2013;42(4):260-5
pubmed: 23379516
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19276-19286
pubmed: 32719141
J Clin Invest. 1998 Feb 15;101(4):746-54
pubmed: 9466968
Arthritis Rheum. 2012 Mar;64(3):671-7
pubmed: 22006178
Ann Rheum Dis. 2009 Mar;68(3):330-6
pubmed: 18375540
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Sci Immunol. 2019 Aug 23;4(38):
pubmed: 31444235
J Immunol. 2007 Dec 15;179(12):8463-9
pubmed: 18056393
Arthritis Res Ther. 2006;8(5):R152
pubmed: 16987426
Clin Vaccine Immunol. 2017 Aug 4;24(8):
pubmed: 28592626
J Periodontol. 2014 Apr;85(4):e72-81
pubmed: 24059638
Front Immunol. 2019 May 21;10:1111
pubmed: 31169830
Science. 2000 Sep 1;289(5484):1508-14
pubmed: 10968781
Arthritis Res Ther. 2010;12(1):R29
pubmed: 20167120
J Transl Med. 2015 Jan 16;13:2
pubmed: 25592233
Nat Immunol. 2014 Oct;15(10):929-937
pubmed: 25151491
J Immunol. 2015 Jun 1;194(11):5150-60
pubmed: 25911752
J Exp Med. 2006 Nov 27;203(12):2673-82
pubmed: 17088434
J Infect Dis. 2015 Jan 15;211(2):274-82
pubmed: 25139016
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
PLoS One. 2014 Oct 17;9(10):e109775
pubmed: 25329467
Clin Rheumatol. 2018 Oct;37(10):2603-2610
pubmed: 30039267
J Am Coll Cardiol. 2012 Oct 16;60(16):1512-20
pubmed: 22999728
Arthritis Res Ther. 2018 Jul 20;20(1):150
pubmed: 30029616
Osteoporos Int. 2017 Oct;28(10):2801-2812
pubmed: 28779302
Arthritis Res Ther. 2020 Oct 16;22(1):245
pubmed: 33066816
Cell Signal. 2019 Dec;64:109395
pubmed: 31449849
J Cell Physiol. 2016 Jun;231(6):1249-60
pubmed: 26491867
Immunol Lett. 2020 Sep;225:74-81
pubmed: 32590119
Osteoporos Int. 2017 Jan;28(1):231-237
pubmed: 27509834
Arthritis Res Ther. 2005;7(2):R241-9
pubmed: 15743470
Arthritis Res Ther. 2010;12(1):R14
pubmed: 20102624
Front Immunol. 2018 Apr 05;9:657
pubmed: 29675022
J Bone Miner Res. 2018 Aug;33(8):1450-1463
pubmed: 29637625
Arthritis Res Ther. 2010;12(5):R196
pubmed: 20961415
Arthritis Res Ther. 2017 Feb 2;19(1):20
pubmed: 28148302
J Immunol. 2013 Jan 15;190(2):605-12
pubmed: 23241888
J Leukoc Biol. 2016 Oct;100(4):823-833
pubmed: 27190305
Lancet. 1994 Jul 2;344(8914):23-7
pubmed: 7912297
Front Immunol. 2013 Feb 04;4:23
pubmed: 23382732
Med Eng Phys. 2008 Jul;30(6):792-9
pubmed: 18164643
Front Endocrinol (Lausanne). 2019 Apr 18;10:236
pubmed: 31057482
Immunol Invest. 2013;42(7):555-622
pubmed: 24004059
Int Orthop. 2014 Jan;38(1):183-92
pubmed: 24100919
Arthritis Res Ther. 2017 Jul 19;19(1):163
pubmed: 28724396
Mod Rheumatol. 2003 Jun;13(2):114-20
pubmed: 24387169
J Exp Med. 2017 Jul 3;214(7):1913-1923
pubmed: 28606987
Rheumatology (Oxford). 2001 Sep;40(9):988-94
pubmed: 11561108
Front Immunol. 2019 Mar 19;10:505
pubmed: 30941138
Endocrinology. 1998 Oct;139(10):4424-7
pubmed: 9751528
Science. 2007 Aug 3;317(5838):666-70
pubmed: 17673663
J Bone Miner Res. 2018 Feb;33(2):250-260
pubmed: 28926125
Immunity. 2013 Nov 14;39(5):925-38
pubmed: 24184057
Arthritis Res Ther. 2017 Feb 10;19(1):28
pubmed: 28183329